Reproducibility (% adequate) | ||||||
---|---|---|---|---|---|---|
Author, publication year | Country | Setting | Study population | Number of patients | FEV1, % | FVC, % |
Primary care practice | ||||||
Schermer et al,I 2009 (current paper) | The Netherlands | Routine care | Adults and children ≥12 years from 15 primary care practices | 1091 | 43 | 40 |
Tuomisto et al, 200827 | Finland | Routine care | Patients from primary care health centres | 489 | 78 to 80a,b | |
Walters et al, 200828 | Australia | Research | Adults from eight primary care practices | 618 | 44 to 76a,c | |
Eaton et al,II 19999 | New-Zealand | Research | Adults and children from 30 primary care practices | 1012 | 3 to 14a,c | |
Schermer et al,I 200322 | The Netherlands | Research | Patients with COPD recruited from 61 primary care practices | 399 | 82d | – |
Zanconato et al,III 200529 | Italy | Research | Children from 10 primary care paediatric practices | 109 | 94a | |
Pulmonary function laboratory | ||||||
Enright et al,IV 200430 | US | Routine care | Adult patients from one outpatient pulmonary function laboratory | 18 000 | >95 | >90 |
Enright et al,V 200015 | US | Routine care | Public schools students aged 9–18 years from middle-income communities | 4000 | 93 | 97 |
Bellia et al,VI 200019 | Italy | Research | Patients ≥65 years attending one of the 24 involved pulmonary or geriatric institutions | 1622 | >94 | >87 |
Stoller et al,II 199731 | US | Research | Patients with severe α1 antitrypsin deficiency, from 37 hospitals | 1090 | >95 | >91 |
Enright et al,VII 199116 | US | Research | Cigarette smokers 35 to 60 years of age included in a clinical trial | 5887 | >99 | – |
Studies conducted in pulmonary function laboratories are included as points of reference. Studies have used different definitions for reproducibility, which limits direct comparison of results.32
Definitions used in the respective studies are:
Two highest FEV1 values <5% and <200 ml;
Largest FEV1 values and largest FVC values ≤200 ml;
Two highest FEV1 values and FVC values ≤5%;
Difference between highest and second-highest FEV1 <150 mL;
FVC and FEV1 values at least 95% of the largest values;
Difference between highest and second-highest value <200ml for FEV1 and FVC;
Difference between highest and second-highest FVC <200ml.
Reproducibility results not reported for FEV1 and FVC separately.
For pre- and postbronchodilator tests respectively.
For usual and trained practices respectively.
Reproducibility calculated without prior selection of acceptable blows according to 1994 American Thoracic Society spirometry guidelines.6
COPD = chronic obstructive pulmonary disease.